You are here

This page is currently under maintenance - please contact the membership team at societymember@sagepub.com if you need assistance with journal subscriptions. Thank you for your patience and we apologize for the inconvenience. 

AI in Precision Oncology

AI in Precision Oncology

Published in Association with Mary Ann Liebert

eISSN: 29930928 | ISSN: 2993091X | Current volume: 3 | Current issue: 4 Frequency: Not Yet Specified
As the only peer-reviewed journal dedicated to the advancement of artificial intelligence applications in clinical and precision oncology, this journal provides a high-profile forum for cutting-edge research and frontmatter highlighting important research and industry-related advances rapidly developing within the field. The use of AI in oncology has the potential to revolutionize cancer care, from early detection to precision medicine. AI can assist in analyzing complex data, such as genomics, imaging, and electronic health records, to improve cancer diagnosis and treatment planning. Moreover, AI can help predict treatment responses, identify new drug targets, and facilitate clinical trials. The Journal's scope includes all aspects of AI in oncology, from basic research to clinical implementation.

"AI in Precision Oncology is more than a scientific or medical journal; it is a mission-driven initiative to harness the power of AI in improving oncology care.” – Dr. Douglas Flora, Editor-in-Chief

AI in Precision Oncology is the only peer-reviewed journal dedicated to the advancement of artificial intelligence applications in clinical and precision oncology. Spearheaded by Editor-in-Chief Douglas Flora, MD and supported by a diverse and accomplished team of international experts, the Journal provides a high-profile forum for cutting-edge research and frontmatter highlighting important research and industry-related advances rapidly developing within the field. 

The use of AI in oncology has the potential to revolutionize cancer care, from early detection to precision medicine. AI can assist in analyzing complex data, such as genomics, imaging, and electronic health records, to improve cancer diagnosis and treatment planning. Moreover, AI can help predict treatment responses, identify new drug targets, and facilitate clinical trials. The Journal's scope includes all aspects of AI in oncology, from basic research to clinical implementation.

AI in Precision Oncology publishes original research articles, reviews, and perspectives on the application of artificial intelligence (AI) in cancer research, diagnosis, and treatment, bringing together researchers, clinicians, and industry experts to share their knowledge and experience in this rapidly evolving field. The Journal helps professionals in the field of oncology understand how artificial intelligence and technology solutions can be applied in an evidence-based, ethical, and thoughtful manner. Overall, the Journal seeks to promote AI's responsible and effective use in oncology, benefiting both healthcare providers and patients.

AI in Precision Oncology coverage includes:

  • AI algorithms for cancer detection, diagnosis, and prognosis
  • AI-based biomarkers for cancer screening and diagnosis
  • AI-assisted imaging analysis for tumor detection and segmentation
  • AI-guided treatment planning and personalized therapy
  • AI-enabled drug discovery and development
  • Machine learning and deep learning in cancer research
  • Natural language processing for electronic health record analysis
  • Ethical and regulatory issues in AI in oncology

AI in Precision Oncology is under the editorial leadership of Editor-in-Chief Douglas Flora, MD, Executive Medical Director, Oncology Services, St. Elizabeth, and supported by a diverse and accomplished team of experts, including David Penberthy, MD, MBA, Associate Professor of Radiation Oncology, Penn State Health; Nikhil Thaker, MD, Chief Medical Informatics Officer, Arizona Oncology; and Scott Penberthy, Managing Director of AI at Google.

Editor-in-Chief
Douglas Flora, MD St Elizabeth Healthcare, Edgewood, KY, USA
Deputy Editor
Nikhil G. Thaker, MD, DHA, MBA, FABS, FAMIA Capital Health, Pennington, NJ, USA and Bayta Systems, PA
Associate Editors
Jasmin Hundal, MD MS MPH  
Toufic Kachaamy, MD, FASGE, AGAF, FACG City of Hope, Phoenix, Phoenix, AZ, USA
Matthew Kurian, MD  
Timothy N. Showalter, MD ArteraAI, Los Altos, CA, USA
Oscar Puig, PhD Delcath Systems, Queensbury, NY, USA
David Waterhouse, MD, MPH Oncology Hematology Care Inc, Cincinnati, OH, USA
Editorial Board Members
Blythe Adamson, PhD, MPH Flatiron Health, New York, NY, USA
Olalekan Ajayi, PharmD, MBA, FACCC Highlands Oncology Group, Fayetteville, AR, USA
Sana Al-Sukhun Al Hyatt Oncology Practice, Amman, Jordan
Christopher Banerji, PhD Alan Turing Institute, London, United Kingdom / University College London Cancer Institute, London, United Kingdom
Larry Bilbrey Tennessee Oncology/Oneoncology, Nashville, TN, USA
Piotr Borkowski, MD Quest Diagnostics / Ameripath, Tampa, FL, USA
Harvey Castro, MD, MBA Chief AI Officer, Phantom Space, Tucson, AZ, USA
Aadel Chaudhuri, MD, PhD Washington University, St. Louis, MO, USA
William C. Cho, PhD Queen Elizabeth Hospital, Hong Kong / SAR, People's Republic of China
Kundan Singh Chufal, MD Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India
Ezra Cohen, MD Chief Medical Officer, Tempus AI - Chicago, IL, USA
Kevin Davies, PhD Mary Ann Liebert, Inc., New Rochelle, NY
Jeroen De Ridder, PhD University Medical Center Utrecht, Utrecht, Netherlands
Adam P. Dicker, MD, PhD, FASTRO, FASCO Thomas Jefferson University, Philadelphia, PA, USA
Cataldo Doria, MD, PhD, MBA, FACS Capital Health Cancer Center, Pennington, NJ, USA
Daniel B. Flora, MD, PharmD St. Elizabeth Healthcare, Edgewood, KY, USA
George Gemelos, PhD Natera, San Carlos, CA, USA
Bethany Hills Grois, JD, MPH  
Leroy Hood, MD, PhD Phenome Health, and ISB (Institute for Systems Biology), Seattle, WA, USA
Sanjay K Juneja, MD Tempus AI, Baton Rouge, LA, USA.
Sean Khozin, MD, MPH CEO Roundtable on Cancer, Project Data Sphere, New York, NY, USA
Teri E. Klein, PhD Stanford University, Stanford, CA, USA
Jill M. Kolesar, PharmD University of Kentucky, Lexington, KY, USA
Jeanne Kowalski, PhD University of Texas at Austin, Austin, TX, USA
Constance Lehman, MD, PhD Harvard Medical School, Boston, MA, USA
Jana Lipkova, PhD University of California Irvine, Irvine, CA, USA
Wei Liu, Ph.D., DABR, FAAPM, FAIMBE Mayo Clinic, Phoenix, AZ, USA
Arturo Loaiza-Bonilla, MD, MSEd Massivebio, New York, NY, USA / St. Luke’s University Health Network, Easton, PA, USA
Amin Mazloom, PhD Exact Sciences, San Diego, CA, USA
Sarah Mcgough, PhD Genentech Inc, South San Francisco, CA, USA
Vishisht Mehta, MBBS, FCCP, DAABIP Comprehensive Cancer Centers of Nevada, Henderson, NV, USA
Michael C. Montalto, PhD Amgen Inc, Thousand Oaks, CA, USA
Mika Newton, BSc xCures, Inc., Oakland, CA, USA
David Penberthy, MD, MBA University of Virginia, Charlottesville, VA, USA
Scott Penberthy, PhD Google Cloud, Palo Alto, CA, USA
Neil Pfister, MD, PhD Alabama Birmingham / CMO of Numenos, AL, USA
Sylvia Plevritis, PhD Stanford University School of Medicine, Stanford, CA, USA
Krishnan R Patel, MD University of Texas-MD Anderson Cancer Center, Houston, TX
Rajeev Ronanki, MS Lyric, King of Prussia, PA, USA
Nihal El Rouby Pharmd, PhD University of Cincinnati, Cincinnati, OH, USA
Afreen Shariff, MD Duke University School of Medicine, Durham, NC, USA
Bradley G. Somer, MD, MBA West Cancer Center & Research Institute, Germantown, TN, USA
Vivek Subbiah, MD Sarah Cannon Research Institute, Nashville, TN, USA
Luma Tabbaa, PhD University of Kent, Canterbury, Kent, United Kingdom
Robert Uzzo, MD, MBA Fox Chase Cancer Center – Temple University Health System, Philadelphia, PA, USA
Mark R. Waddle, M.D Mayo Clinic, Rochester, MN, USA
  • Emerging Sources Citation Index (ESCI) - Web of Science